Cargando…

Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course

BACKGROUND: Imatinib mesylate is the gold standard for the treatment of all phases of Philadelphia-positive chronic myeloid leukemia. Patients on imatinib treatment may develop cytopenia due to drug toxicity. This study aimed to determine the types, grades, and time course of cytopenia in CML patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	McLigeyo, Angela, Rajab, Jamilla, Ezzi, Mohammed, Oyiro, Peter, Bett, Yatich, Odhiambo, Andrew, Ong'ondi, Matilda, Mwanzi, Sitna, Gatua, Mercy, Abinya, NAOthieno-
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240645/ https://www.ncbi.nlm.nih.gov/pubmed/32454829 http://dx.doi.org/10.1155/2020/7696204

Ejemplares similares

Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study
por: McLigeyo, Angela, et al.
Publicado: (2022)

Prevalence and Predictors of Cisplatin-Induced Peripheral Neuropathy at the Kenyatta National Hospital
por: Ezzi, Mohammed S., et al.
Publicado: (2019)

Molecular Profiling of Kenyan Acute Myeloid Leukemia Patients
por: Gatua, Mercy, et al.
Publicado: (2022)

Plasma Cell Leukemia: A Review of 3 Cases Managed in Kenya
por: Ong'ondi, Matilda, et al.
Publicado: (2021)

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
por: Rea, Delphine, et al.
Publicado: (2020)

Urinary bladder metastasis from breast cancer: a rare cause of hematuria
por: Gitau, Samuel Nguku, et al.
Publicado: (2020)

Reply: The long-term response to imatinib treatment of CML
por: Michor, F
Publicado: (2007)

MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
por: Harrach, S, et al.
Publicado: (2016)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Unusual presentation of hepatocellular carcinoma: Case report and review of literature
por: Loyal, Poonamjeet, et al.
Publicado: (2021)

WCN23-0208 THE PREVALENCE AND SHORT-TERM OUTCOMES OF ACUTE KIDNEY INJURY IN PATIENTS HOSPITALIZED WITH COVID-19 INFECTION
por: OGANGA, M., et al.
Publicado: (2023)

Changes in Blood Pressure Levels and Antihypertensive Medication Use before and after Renal Transplantation among Patients in Nairobi, Kenya: A Comparative Cross-Sectional Study
por: Kubo, Mary N., et al.
Publicado: (2016)

Primary rectal melanoma in an African female: a case report
por: Kuka, Werimo Pascal, et al.
Publicado: (2022)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
por: Stella, Stefania, et al.
Publicado: (2019)

Clinical characteristics and outcomes of atrial fibrillation and flutter at the Aga Khan University Hospital, Nairobi
por: Shavadia, Jay, et al.
Publicado: (2013)

HIV Prevalence and Characteristics Among Patients With AIDS-Defining and Non–AIDS-Defining Cancers in a Tertiary Hospital in Kenya
por: Muturi, Diana, et al.
Publicado: (2023)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

Clonal evolution in a patient with CML detected by FISH precedes imatinib treatment failure
por: Enriquez, Virginia, et al.
Publicado: (2007)

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy()
por: Aliano, Stefania, et al.
Publicado: (2013)

Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo
por: Li, Hui, et al.
Publicado: (2016)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019)

Survival probability and factors associated with time to loss to follow-up and mortality among patients on antiretroviral treatment in central Kenya
por: Wekesa, P., et al.
Publicado: (2022)

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
por: Narita, Miwako, et al.
Publicado: (2010)

Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients
por: Mohajeri, Ehsan, et al.
Publicado: (2015)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income
por: Radich, Jerald P., et al.
Publicado: (2022)

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir
por: Azad, Niyaz A, et al.
Publicado: (2018)

Campylobacter Jejuni and Cytopenias
por: Schattner, Ami
Publicado: (2013)

Cytopenias in Transplant Patients
por: Barry, Maura, et al.
Publicado: (2018)

Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
por: Valent, Peter
Publicado: (2007)

Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3
por: Wang, Houcai, et al.
Publicado: (2016)

Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib
por: Jin, Yanli, et al.
Publicado: (2016)

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018)

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
por: El Jurdi, Najla, et al.
Publicado: (2016)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
por: Millot, Frédéric, et al.
Publicado: (2021)

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients
por: Hamza, Marwa S, et al.
Publicado: (2022)

Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya
por: Wekesa, Paul, et al.
Publicado: (2020)

Predialysis Care Experience Among Patients With CKD at a Teaching Hospital in Kenya
por: Kabinga, Samuel K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6v18ngku570r8haii6kjpfbkd1